Tesofensine Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Tesofensine evidence and protocol review

Metabolic Research compound PowderCapsuleLiquid needs_revision Best effort · source review pending

Also known as: NS2330

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

100 mg, 500 mg, 1 g

Storage

No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Best-Effort Research Profile

Tesofensine (NS2330) is a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin), originally investigated for Parkinson's and Alzheimer's disease before incidental significant weight loss was observed, redirecting development toward obesity. A 24-week randomized, double-blind, placebo-controlled Phase 2 trial found dose-dependent mean weight loss of 4.5%, 9.2%, and 10.6% at 0.25mg, 0.5mg, and 1.0mg doses respectively (with diet) versus diet-plus-placebo - suggesting the 0.5mg dose could produce roughly double the weight loss of anti-obesity drugs approved at the time of the study. The most common adverse events were dry mouth, nausea, constipation, and insomnia; the 0.5mg dose increased heart rate by 7.4 bpm versus placebo without significant blood pressure change at 24 weeks - a cardiovascular safety signal relevant to its now-longer development timeline.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Long (multi-day; specific figure varies across sources - verify before publishing precise numbers)

Onset

Weight-loss effects assessed over a 24-week Phase 2 RCT

Administration Routes (Research)

Oral

Reported Research Effects

Dose-dependent weight loss: 4.5-10.6% at 24 weeks across studied doses
Blocks dopamine, norepinephrine, and serotonin reuptake
Originally studied for Parkinson's/Alzheimer's before pivoting to obesity indication

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

0.25, 0.5, or 1 mg/day [Oral; 24 weeks; Daily]Source: randomized Phase 2 obesity trial

Research Notes

Tesofensine is not FDA-approved; sympathomimetic cardiovascular and neuropsychiatric effects require careful evaluation.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

Tesofensine Phase 2 obesity trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/18950853/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.